$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000112623423000058 Filed on May 05, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$527.0K	$691.0K	$111.0K
YoY Change	30.77%	522.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.146M	$4.357M	$3.621M
YoY Change	12.6%	20.33%	-9.48%
% of Gross Profit
Research & Development	$6.024M	$4.369M	$4.221M
YoY Change	29.69%	3.51%	-9.42%
% of Gross Profit
Depreciation & Amortization	$9.000K	$9.000K	$12.00K
YoY Change	-550.0%	-25.0%	-92.94%
% of Gross Profit
Operating Expenses	$10.17M	$8.726M	$7.842M
YoY Change	22.13%	11.27%	-8.99%
Operating Profit	-$9.643M	-$8.035M	-$7.731M
YoY Change	21.69%	3.93%	-10.28%
Interest Expense	$559.0K	$570.0K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$683.0K	$689.0K	$11.00K
YoY Change	753.75%	6163.64%	-178.57%
Pretax Income	-$8.960M	-$7.346M	-$7.720M
YoY Change	14.23%	-4.84%	-10.55%
Income Tax	-$29.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.931M	-$7.346M	-$7.720M
YoY Change	13.86%	-4.84%	-10.55%
Net Earnings / Revenue	-1694.69%	-1063.1%	-6954.95%
Basic Earnings Per Share	-$1.09	-$0.89	-$0.92
Diluted Earnings Per Share	-$1.09	-$0.89	-$0.92
COMMON SHARES
Basic Shares Outstanding	8.171M shares	8.219M shares	8.358M shares
Diluted Shares Outstanding	8.165M shares	8.240M shares	8.358M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.85M	$57.98M	$86.76M
YoY Change	-36.05%	-33.17%	-23.96%
Cash & Equivalents	$37.86M	$44.04M	$86.80M
Short-Term Investments	$12.99M	$13.95M
Other Short-Term Assets	$4.899M	$5.070M	$5.753M
YoY Change	-8.05%	-11.87%	8.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$233.0K	$200.0K
Total Short-Term Assets	$55.98M	$63.25M	$92.65M
YoY Change	-34.13%	-31.73%	-22.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.00K	$52.00K	$69.00K
YoY Change	-35.71%	-24.64%	-31.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$390.0K	$472.0K	$545.0K
YoY Change	-16.13%	-13.39%	18.22%
TOTAL ASSETS
Total Short-Term Assets	$55.98M	$63.25M	$92.65M
Total Long-Term Assets	$390.0K	$472.0K	$545.0K
Total Assets	$56.37M	$63.73M	$93.19M
YoY Change	-34.03%	-31.62%	-22.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$279.0K	$837.0K	$1.799M
YoY Change	-67.33%	-53.47%	403.92%
Accrued Expenses	$6.087M	$3.948M	$3.098M
YoY Change	66.4%	27.44%	-29.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.545M	$5.017M	$5.242M
YoY Change	35.45%	-4.29%	5.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$189.0K	$0.00
YoY Change
Other Long-Term Liabilities	$6.167M	$6.000M	$6.131M
YoY Change	1.51%	-2.14%	0.51%
Total Long-Term Liabilities	$6.167M	$6.189M	$6.131M
YoY Change	1.51%	0.95%	0.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.545M	$5.017M	$5.242M
Total Long-Term Liabilities	$6.167M	$6.189M	$6.131M
Total Liabilities	$12.71M	$11.21M	$11.37M
YoY Change	16.55%	-1.47%	2.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.8M	-$134.8M	-$104.1M
YoY Change	28.37%	29.47%	39.56%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)			$119.0K
YoY Change			170.45%
Treasury Stock Shares			9.896K shares
Shareholders Equity	$43.66M	$52.52M	$81.82M
YoY Change
Total Liabilities & Shareholders Equity	$56.37M	$63.73M	$93.19M
YoY Change	-34.03%	-31.62%	-22.38%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$8.931M	-$7.346M	-$7.720M
YoY Change	13.86%	-4.84%	-10.55%
Depreciation, Depletion And Amortization	$9.000K	$9.000K	$12.00K
YoY Change	-550.0%	-25.0%	-92.94%
Cash From Operating Activities	-$6.685M	-$9.197M	-$8.033M
YoY Change	-7.73%	14.49%	-22.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.083M	-$2.463M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$1.083M	-$2.463M	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-574.0K	-$309.0K	-$18.00K
YoY Change	28600.0%	1616.67%	-89.16%
NET CHANGE
Cash From Operating Activities	-6.685M	-$9.197M	-$8.033M
Cash From Investing Activities	1.083M	-$2.463M	$0.00
Cash From Financing Activities	-574.0K	-$309.0K	-$18.00K
Net Change In Cash	-6.176M	-$11.97M	-$8.051M
YoY Change	-14.78%	48.66%	-152.2%
FREE CASH FLOW
Cash From Operating Activities	-$6.685M	-$9.197M	-$8.033M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35342
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	LUMOS PHARMA, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1491350
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4200 Marathon Blvd #200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78756
CY2023Q1	dei	City Area Code CityAreaCode	512
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	215-2630
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	LUMO
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8170526	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44038000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56007000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	13945000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	11352000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5070000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4427000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	200000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	223000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	63253000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	72009000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	420000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	230000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	472000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	283000	usd
CY2023Q1	us-gaap	Assets Assets	63725000	usd
CY2022Q4	us-gaap	Assets Assets	72292000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	837000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	275000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3948000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6200000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	232000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5017000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6708000	usd
CY2023Q1	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	usd
CY2022Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	189000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6189000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6000000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11206000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12708000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8200043	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8283708	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8183296	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8267968	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	81000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	82000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	16747	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	15740	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	174000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	170000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187446000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187164000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134829000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127483000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	52519000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	59584000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63725000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72292000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	691000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111000	usd
CY2023Q1	us-gaap	Revenues Revenues	691000	usd
CY2022Q1	us-gaap	Revenues Revenues	111000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4369000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4221000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4357000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3621000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8726000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7842000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8035000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7731000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	570000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	689000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7346000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8239941	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8239941	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8239941	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8357969	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8357969	shares
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7342000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7720000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	88977000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	565000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	81817000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	59584000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	305000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7346000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	52519000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7346000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	586000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	565000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	usd
CY2023Q1	us-gaap	Other Noncash Income OtherNoncashIncome	136000	usd
CY2022Q1	us-gaap	Other Noncash Income OtherNoncashIncome	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	643000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1002000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-22000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1689000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	119000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9197000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8033000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2463000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2463000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	305000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	13000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-309000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11969000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8051000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56007000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94809000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44038000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86758000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Organization and Nature of Operations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in this Quarterly Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing our clinical program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">focused on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which there is currently a significant unmet need for safe and effective therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ticker symbol “LUMO.”</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a business combination (the “Merger”) between</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger closed on March 18, 2020, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secretagogue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibutamoren (“LUM-201”), a potential oral therapy for idiopathic pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. However, the Company believes that its existing cash, cash equivalents and short-term investments of approximately $58.0 million as of March 31, 2023 will be sufficient to allow the Company to fund its operations into the third quarter of 2024, which is inclusive of the primary read out of its Phase 2 clinical trial of LUM-201 in PGHD (“OraGrowtH210 Trial”) and OraGrowtH212 Trial, each of which is expected to occur in the fourth quarter of 2023. If available liquidity becomes insufficient to meet the Company’s obligations as they come due, our future operations will be reliant on additional equity or financing arrangements. There can be no assurances that, in the event that the Company requires additional financing, such financing will be available on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</span></div>
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	58000000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	56977000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include stock-based compensation, accruals for clinical trials and deferred tax assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the estimates and assumptions used in preparation of our condensed consolidated financial statements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our knowledge of current events and actions that we may undertake in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are appropriate, actual results could differ from those estimates, and any such differences may be material.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company’s significant accounting policies are consistent with those discussed in Note 2 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of its consolidated financial statements included in the Company’s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 </span>Annual Report filed on Form 10-K with the SEC on March 7, 2023.
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	400000	usd
CY2022Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	100000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43027000	usd
CY2023Q1	nlnk	Short Term Investments Fair Value Disclosure ShortTermInvestmentsFairValueDisclosure	13945000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	56972000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	55342000	usd
CY2022Q4	nlnk	Short Term Investments Fair Value Disclosure ShortTermInvestmentsFairValueDisclosure	11352000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	66694000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	56972000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	66703000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	66694000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1617000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3729000	usd
CY2023Q1	nlnk	Accrued Clinical And Contract Manufacturing Expenses Current AccruedClinicalAndContractManufacturingExpensesCurrent	1948000	usd
CY2022Q4	nlnk	Accrued Clinical And Contract Manufacturing Expenses Current AccruedClinicalAndContractManufacturingExpensesCurrent	1800000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	383000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	671000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3948000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6200000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	586000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	565000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4300000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7346000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7720000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8239941	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8239941	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8357969	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8357969	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1567049	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1510369	shares

Files In Submission

Name	View Source	Status
0001126234-23-000058-index-headers.html	Edgar Link	pending
0001126234-23-000058-index.html	Edgar Link	pending
0001126234-23-000058.txt	Edgar Link	pending
0001126234-23-000058-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lumo-2023331x10qxex3111.htm	Edgar Link	pending
lumo-2023331x10qxex3121.htm	Edgar Link	pending
lumo-2023331x10qxex3211.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlnk-20230331.htm	Edgar Link	pending
nlnk-20230331.xsd	Edgar Link	pending
nlnk-20230331_g1.jpg	Edgar Link	pending
nlnk-20230331_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
nlnk-20230331_def.xml	Edgar Link	unprocessable
nlnk-20230331_lab.xml	Edgar Link	unprocessable
nlnk-20230331_cal.xml	Edgar Link	unprocessable
nlnk-20230331_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nlnk-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2023 Q2 Form 10-Q Financial Statement

#000112623423000058 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2023 Q2 Form 10-Q Financial Statement

#000112623423000058 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo